Indirect comparison of ixekizumab versus risankizumab for up to 12 weeks of treatment in patients with moderate-to-severe psoriasis

被引：0
|
作者：
Gottlieb, Alice B. [1 ]
Ramot, Yuval [2 ]
Smith, Saxon D. [3 ]
Saure, Daniel [4 ]
Schuster, Christopher [5 ]
Schacht, Alexander [4 ]
Thaci, Diamant [6 ]
机构：
[1] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA
[2] Hadassah Hebrew Univ, Med Ctr, Dept Dermatol, Jerusalem, Israel
[3] Univ Sydney, Sydney Med Sch, Discipline Dermatol, Sydney, NSW, Australia
[4] Lilly Deutschland GmbH, Bad Homburg, Germany
[5] Eli Lilly GmbH, Vienna, Austria
[6] Univ Hosp Schleswig Holstein, Inst & Comprehens Ctr Inflammat Med, Campus Lubeck, Lubeck, Germany
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2019年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
9775
引用
收藏
页码：AB226 / AB226
页数：1
相关论文
共 50 条
  • [41] Indirect comparison of Ixekizumab versus Guselkumab up to week 12
    Gottlieb, A. B.
    Ramot, Y.
    Smith, S. D.
    Saure, D.
    Schacht, A.
    Dossenbach, M.
    Wilhelm, S.
    Thaci, D.
    Eppendorfer, S.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 120 - 120
  • [42] Ixekizumab for the treatment of pediatric patients with moderate to severe plaque psoriasis
    Cather, Jennifer Clay
    Young, Chaney T.
    Young, Melody S.
    Cather, J. Christian
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (08) : 983 - 990
  • [43] Indirect comparison of ixekizumab versus guselkumab up to week 12
    Gottlieb, A.
    Ramot, Y.
    Smith, S.
    Saure, D.
    Schacht, A.
    Dossenbach, M.
    Wilhelm, S.
    Thaci, D.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 90 - 90
  • [44] Indirect comparison of ixekizumab versus guselkumab up to week 12
    Gottlieb, A.
    Ramot, Y.
    Smith, S.
    Saure, D.
    Schacht, A.
    Dossenbach, M.
    Wilhelm, S.
    Thaci, D.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (05) : S3 - S3
  • [45] Safety of Ixekizumab in comparison to fumaric acid esters and methotrexate over 24 weeks in systemic naive patients with moderate-to-severe plaque-psoriasis
    Gambichler, T.
    Schacht, A.
    Saure, D.
    Dossenbach, M.
    Leutz, A.
    Gerdes, S.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 121 - 122
  • [46] Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
    Gordon, K. B.
    Blauvelt, A.
    Papp, K. A.
    Langley, R. G.
    Luger, T.
    Ohtsuki, M.
    Reich, K.
    Amato, D.
    Ball, S. G.
    Braun, D. K.
    Cameron, G. S.
    Erickson, J.
    Konrad, R. J.
    Muram, T. M.
    Nickoloff, B. J.
    Osuntokun, O. O.
    Secrest, R. J.
    Zhao, F.
    Mallbris, L.
    Leonardi, C. L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (04): : 345 - 356
  • [47] Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
    Egeberg, Alexander
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (21): : 2101 - 2102
  • [48] Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis
    Egeberg, Alexander
    Bryld, Lars Erik
    Skov, Lone
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (01) : 173 - 178
  • [49] The Effectiveness of Risankizumab Following Guselkumab Failure in Moderate-to-Severe Psoriasis Patients: A Retrospective Study
    Hamm, Camille
    Ramsoondar, Nusha
    McGillis, Michaela
    Waugh, Miranda
    Gooderham, Melinda
    Giroux, Lyne L.
    [J]. JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2023, 27 (05) : 476 - 480
  • [50] Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy
    Giunta, Alessandro
    Ventura, Alessandra
    Chimenti, Maria Sole
    Bianchi, Luca
    Esposito, Maria
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 1643 - 1651
12345